SCHEMBL6726423

SCHEMBL6726423

Cc1cc(-c2cnc(OC(=O)N3CCN(S(=O)(=O)N4Cc5ccc(Cl)cc5C4)CC3)nc2)ccn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.37
WNT3A P56704 3/20 0.35
POLB P06746 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
GLA P06280 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
IDE P14735 1/20 0.35
PIK3CB P42338 1/20 0.34
HSD17B10 Q99714 1/20 0.34
AKR1C3 P42330 2/20 0.33
CYP11B2 P19099 1/20 0.33
KMT2A Q03164 1/20 0.33
GAA P10253 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33
AKR1C1 Q04828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6737705 0.89 ALDH1A1 (0.37) MAPTSMN1; SMN2ALDH1A1LMNAGLA
SCHEMBL6726361 0.83 MAPT (0.35) MAPTWNT3APOLBSMN1; SMN2ALDH1A1
SCHEMBL6730095 0.82 SLC6A7 (0.47) MAPTPOLBSMN1; SMN2LMNATSHR
SCHEMBL6725627 0.75 CYP11B2 (0.36) MAPTALDH1A1CYP11B2FNTAFNTB
SCHEMBL6730955 0.74 TRPA1 (0.35) MAPTWNT3AAKR1C3CYP11B2FNTA
SCHEMBL6736462 0.72 WNT3A (0.38) WNT3AIDENOS1NOS2
SCHEMBL6726229 0.72 TLR8 (0.41) MAPTWNT3ASMN1; SMN2ALDH1A1LMNA
SCHEMBL6725385 0.72 WNT3A (0.37) MAPTWNT3ASMN1; SMN2ALDH1A1LMNA
SCHEMBL6729950 0.71 AKR1C3 (0.44) MAPTPOLBSMN1; SMN2LMNAAKR1C3
SCHEMBL6726691 0.71 F10 (0.38) POLBALDH1A1LMNATSHRF10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6747023-B1 INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-08 US disclosed
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-29 US disclosed
EP-1104754-A1 NOVEL SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction F2, CYC1, SULT2A1 MAPT 4665/4885WNT3A 3481/4885POLB 1782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.